The next three to five years would see some of the most important cardio-vascular, diabetic and oncology molecules going off-patent in the Indian market. This could trigger launches of generic versions by local pharma players, and thereby a major drop in their prices. Industry experts expect the sharpest ...
Read more: Price crash ahead? Key diabetes, cancer drugs to go off-patent in India